| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.28 | 0.05 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.05 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.05 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.23 | 0.06 |